BioCentury | Jun 27, 2017
Distillery Techniques

Biomarkers

...in unaffected subjects. In 124 patients treated with Cymbalta duloxetine and 61 patients treated with Lexapro...
...four miRNAs were associated with low posttreatment disease scores. In another 158 patients treated with Lexapro...
...A/S , Allergan plc , Mitsubishi Tanabe Pharma Corp. and Mochida Pharmaceutical Co. Ltd. market Lexapro...
BioCentury | Apr 21, 2016
Targets & Mechanisms

Structural SERT-ainty

...at the company. Lundbeck and Allergan plc market Celexa citolapram for depression, and Lundbeck markets Cipralex...
BioCentury | Dec 7, 2015
Clinical News

Lexapro escitalopram oxalate regulatory update

...and Mitsubishi Tanabe Pharma Corp. (Tokyo:4508, Osaka, Japan) said Japan approved an expanded label for Lexapro...
...inhibitor (SSRI) is marketed in Japan to treat depression. Mochida, which has Japanese rights to Lexapro...
...CSE:LUN), Copenhagen, Denmark Mochida Pharmaceutical Co. Ltd. (Tokyo:4534), Tokyo, Japan Product: Lexapro escitalopram oxalate ( MLD-55...
BioCentury | Aug 20, 2015
Company News

Lundbeck restructuring

...and R&D costs rather than administrative expenses. The company posted declines in sales of antidepressant Cipralex...
BioCentury | Nov 10, 2014
Finance

Convert resurgence

...partnered with Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA), increased 7% to DKK372M ($63.4M). Sales of antidepressant Cipralex...
BioCentury | Aug 11, 2014
Finance

Highlights of weekly biotech stock moves

...partnered with Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA), increased 9% to DKK371M ($68M). Sales of antidepressant Cipralex...
BioCentury | May 12, 2014
Finance

Zeroing in on immunity

...partnered with Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA), increased 8% to DKK376M ($69.3M). Sales of antidepressant Cipralex...
BioCentury | Feb 24, 2014
Finance

Tree hugging

...fell by 32% to $3.1 billion due to the loss of patent exclusivity for antidepressant Lexapro...
BioCentury | Feb 10, 2014
Finance

Confident roll of the dice(r)

...partnered with Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA), increased 8% to DKK346M ($63.9M). Sales of antidepressant Cipralex...
BioCentury | Nov 11, 2013
Finance

OrbiMed's high five

...revenues were DKK3.6B ($645.3M), flat from 3Q12. The Street was expecting DKK3.4B. Sales of antidepressant Lexapro...
...partnered with Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA), increased 6% to DKK349M ($63.3M). Sales of antidepressant Cipralex...
Items per page:
1 - 10 of 196